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Abstract
Background: How to maintain “gut health” is a goal for scientists throughout the world. Therefore, microbiota
management models for testing probiotics, prebiotics, and synbiotics have been developed.
Methods: The SHIME® model was used to study the effect of Lactobacillus acidophilus 1014 on the fermentation
pattern of the colon microbiota. Initially, an inoculum prepared from human feces was introduced into the reactor
vessels and stabilized over 2-wk using a culture medium. This stabilization period was followed by a 2-wk control
period during which the microbiota was monitored. The microbiota was then subjected to a 4-wk treatment period
by adding 5 mL of sterile peptone water with L. acidophilus CRL1014 at the concentration of 108 CFU/mL to vessel
one (the stomach compartment). Plate counts, Denaturing Gradient Gel Electrophoresis (DGGE), short-chain fatty
acid (SCFA) and ammonium analyses were carried out for monitoring of the microbial community from the colon
compartments.
Results: A significant increase (p < 0.01) in the Lactobacillus spp. and Bifidobacterium spp. populations was observed
during the treatment period. The DGGE obtained showed changes in the lactobacilli community from the colon
compartments of the SHIME® reactor. The (SCFA) concentration increased (p < 0.01) during the treatment period,
due mainly to significant increased levels of acetic, butyric, and propionic acids. However, ammonium
concentrations decreased during the same period (p < 0.01).
Conclusions: This study showed the beneficial influence of L. acidophilus CRL 1014 on microbial metabolism and
lactobacilli community composition for improving human health.
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Background
“Gut health” is a term increasingly used in the scientific
literature and by the food industry. It covers multiple
positive aspects of the gastrointestinal (GI) tract, such as
the effective digestion and absorption of food, the ab-
sence of GI illness, normal and stable gut microbiota,
effective immune status and a state of well-being [1].
Gut microbiota is composed of different bacterial spe-
cies, which are involved in the metabolism of nutrients,
the maturation of the intestinal epithelium, vasculature
and lymphoid tissue, and protection against pathogens [2].
The composition of the intestinal microbiota varies along
the gastrointestinal tract in its different compartments [3]
and also within specific compartments. For instance, the
mucosa seems to harbor a different microbiota than the
lumen and very few microorganisms are in direct con-
tact with the epithelium [4]. The majority of bacteria in
the adult gut are non-sporing anaerobes, the most
numerous include Bacteroides spp., Bifidobacterium
spp., Eubacterium spp., Clostridium spp., Fusobacterium
spp., and various gram-positive cocci. Bacteria that
are present in lower numbers include Enterococcus
spp., Enterobacteriaceae, methanogens, and dissimila-
tory sulfate-reducing bacteria [5,6].
Currently, how to maintain intestinal health is a major
challenge in medicine. There are many strategies to im-
prove gut health, such as the consumption of a balanced
diet that includes large quantities of vegetables [7] and
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moderate consumption of red meat [8]. Other options
involve using the intestinal microbiome or GI barrier
modulators, such as probiotics or prebiotics [9]. Indeed,
it has been shown that chronic bowel diseases, such as
IBD, are associated with adherence of commensal bac-
teria to the otherwise sterile intestinal epithelium [10].
Selected probiotics might prevent the adhesion of patho-
genic bacteria to the intestinal mucosa [11] or restore
leaky gut by improving the molecular composition of
tight junctions [12].
Some strains of Bifidobacterium and Lactobacillus
have been associated with improved health, resulting in
the emergence of probiotics science, the delivery of
specific bacteria to the colon or the administration of
dietary components that promote the growth of specific
bacteria with defined metabolic functions [13].
The Simulator of the Human Intestinal Microbial
Ecosystem (SHIME®) is an in vitro system proven to be a
very useful model for nutrition studies, in terms of ana-
lysis of the intestinal microbial community composition
[14-16]. This study aimed to evaluated the interactions
of Lactobacillus acidophilus CRL1014 with native micro-
biota after passing through simulated stomach and small
intestine conditions. Finally, the capacity to temporarily
modulate the intestinal microbiota after oral administra-
tion was investigated using SHIME® reactor.
Methods
Preparation of L. acidophilus CRL 1014 cells
At weekly intervals, a pure culture of L. acidophilus CRL
1014 (CERELA, San Miguel de Tucumán, Argentina)
was inoculated into De Man, Rogosa and Sharpe (MRS)
broth (Acumedia, Baltimore, USA). Cultures were
harvested during the exponential growth, after, they were
centrifuged (4000 × g, 10 min, 4°C) and washed with
sterile peptone water. The L. acidophilus CRL1014 cells
were kept at the concentration of 108 CFU/mL in sterile
peptone water until use [17].
Long-term SHIME® run
The SHIME® is a simulator of the human intestinal mi-
crobial ecosystem [18,19] in which environmental condi-
tions (pH, residence time, inoculum, and temperature)
are controlled to resemble those found in vivo. A
SHIME® system consists of five double-jacketed vessels,
simulating the stomach, the small intestine, and the as-
cending, transverse and descending colon, with a total
retention time of 72 h (Additional file 1: Figure S1). The
reactor setup and the composition of the liquid feed
(Table 1), which entered the system three times per day,
were previously described by Possemiers et al. [14].
The three colon vessels of the SHIME® reactor were
inoculated with bacteria from a fecal sample of a healthy
22-year-old adult female with no history of antibiotic
treatment 6 months prior to the study. Aliquots (10 g)
of fresh fecal samples were diluted and homogenized
with 100 mL of sterilized phosphate buffer (0.1 mol/L,
pH 7), containing 1 g/L sodium thioglycolate as the
reducing agent.
The microbial inoculum was stabilized over a period of
2-wk on a carbohydrate-based medium and allowed to
adapt to the specific environmental conditions of the as-
cending, transverse and descending colon, in terms of pH
range, retention time and available carbon sources [14,15].
Upon stabilization, the SHIME® run included 2- wk of
basal period (to quantify all steady-state bacterial parame-
ters which were used as starting point to evaluate the
effect of a specific treatment), and a 4-wk of treatment
period, in which 5 mL of 108 CFU/mL of L. acidophilus
CRL 1014 were added once per day to the stomach com-
partment. Finally, a 2-week washout period without the
addition of L. acidophilus CRL 1014 was observed.
Microbiological analysis
At weekly intervals, throughout the entire experimental
period, (basal, treatment and washout), 5 mL samples
were collected from the reactors for microbiological exam-
inations. The analysis of the intestinal microbiota compos-
ition was based on the enumeration of total aerobic and
anaerobic bacteria, Enterococcus spp., Lactobacillus spp.,
Bifidobacterium spp., enterobacteria, and Clostridium spp.
One mL of a sample taken from each reactor was
suspended in 99 mL of peptone water. Serial dilutions
were prepared and inoculated into selective culture media,
as follows: total aerobic and anaerobic counts: Standard
Methods agar (Acumedia, Baltimore, USA; 37°C/48 h);
Enterococcus spp.: KF Streptococcus agar (Acumedia,
Baltimore, USA; 37°C/48 h) [16]; Lactobacillus spp.: MRS
agar (Merck, Germany; 37°C/48 h, under anaerobiosis). For
Bifidobacterium spp. counts was used the Bifidobacterium
formulated medium BIM-25 (Difco, France; 37°C/72 h,
Anaerobic System, Probac, Brazil) according Munoa &
Table 1 Ingredients (g) employed for each liter of the
basal feed used in the Shime reactor
Ingredient Quantity necessary for 1 L
Arabinogalactan (Sigma, USA) 1.0
Pectin (Sigma, USA) 2.0
Xylan (Sigma, USA) 1.0
Potato starch (Unilever, Brazil) 3.0
Glucose (Sigma, USA) 0.4
Yeast extract (Sigma, USA) 3.0
Peptone (Sigma, USA) 1.0
Mucin (Sigma, USA) 4.0
Cystein (Sigma, USA) 0.5
Sterile distilled water qsp
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Pares [20], Enterobacteria: MacConkey agar (Acumedia,
Baltimore, USA; 37°C/48 h) and Clostridium spp.: RCA
Agar (Difco, France; 37°C/48 h, Anaerobic System, Probac,
Brazil) [21].
Analysis of short-chain fatty acids and ammonium
Once a week, throughout the entire experimental period
(basal, treatment and washout), samples were collected
from the reactors for analysis SCFA and ammonium.
The analysis was carried out in triplicates.
Every week, the levels of short-chain fatty acids (SCFA)
were determined from samples collected from the reac-
tors and frozen to −20°C. The SCFA were extracted with
diethyl ether and determined using a gas chromatograph
equipped with a flame-ionization gas detector, a capillary
split/splitless injector and an HP-INNOWAX column
with a 30 m × 0.25 mm × 0.25 μm inlet (Shimadzu
GC2010), using hydrogen as the carrier gas at a flow rate
of 1.56 mL/min. The temperatures of the column, injector
and detector were 170, 250 and 280°C, respectively [22].
The ammonia content was determined using a selective
ion meter (710A model, Orion) coupled to an ammonia
selective-ion electrode (Orion 95–12). The apparatus was
calibrated using 0.1 M standard ammonium chloride solu-
tions, at the concentrations of 10, 100, and 1000 mg/L of
ammonia. To every 25 mL of sample, 0.5 mL of ISA solu-
tion (Ionic Strength Adjuster, Orion – a pH-adjusting and
ionic force solution) was added. All measurements were
carried out at 25°C [23].
Composition of the Lactobacillus community
DNA was extracted from 2 mL of sample using the
QIAamp DNA Stool Mini Kit (Qiagen, Hilden, Germany),
according to the manufacturer’s protocol. DNA yield was
quantified using a NanoDrop ND-1000 spectrophotom-
eter (NanoDrop Technologies, Willmington, USA).
DGGE analysis
The diversity of the Lactobacillus community in samples
taken throughout model operation was assessed by
DGGE. To prevent a low amplicon yield a nested PCR
approach was used as previously described [24]. This in-
volved a first round of PCR with primers Bact27f (5′-
GTTTGATCCTGGCTCAG-3′) [25] and 1492R (5′- CGG
CTA CCT TGT TAC GAC-3′) [26], followed by a second
PCR with primers Lab159f (5′-GGAAACAGATGCTAA
TACCG-3′) and Lab677-GCr (5′-GCCCGGGGCGCGCC
CCGGGCGGGGCGGGGGCACGGGGGGGCACCGCT
ACACATGGAG-3′) [24].
PCR was performed using the GoTaq® Green Master
Mix kit (Promega, USA). Samples were amplified in a
Veriti® 96-Well Thermal Cycler (Applied Biosystems,
USA) by using the following program: initial denatur-
ation at 94°C for 2 min; 35 cycles of denaturation at 94°C
for 30 s, annealing at primer-specific temperature for
40 s, elongation at 72°C for primer-specific time, and
extension at 72°C for 5 min, followed by a final cooling
to 4°C. The annealing temperature and elongation time
was set at 52°C/1.30 min with primers Bact27f and
1492r and 60°C/1 min with primers Lab159f and
Lab677-GCr. The PCR products that were used as tem-
plates in nested PCR were purified with the QIAquick
PCR Purification Kit (Qiagen, USA).
DGGE analysis of PCR amplicons was based on the
protocol described by Muyzer et al. [27] by using the
DCode System (Bio-Rad Laboratories, Hercμles, CA,
USA). Electrophoresis was done as described previously
[24] in an 8% polyacrylamide gel with a denaturant gra-
dient of 30–50% (100% was defined as 40% formamide
and 7 M urea) for 16 h at 85 V in a 0.5× TAE buffer at a
constant temperature of 60°C. Gels were stained with
silver nitrate by the method of Sanguinetti et al. [28],
scanned at 400 d.p.i., and further analyzed by the
BioNumerics 6.0 software (Applied Maths). The dis-
tance matrices of each DGGE based on the Pearson
correlation similarity coefficient to cluster the samples
was analyzed using the BioNumerics software (Applied
Maths).
Bands of interest in the lactobacilli community fin-
gerprint were excised from the gel and transferred into
25 μl of TE buffer, and incubated overnight at 37°C to
allow diffusion of the DNA. Two microliters of the
eluted DNA were used for reamplification with the
GC-clamped primer by using the conditions described
above and the PCR products generated were checked
by DGGE. Only PCR products which yielded a single
band and comigrated with the original band were puri-
fied by the QIAprep spin miniprep kit (Qiagen, USA)
and were subjected to DNA sequence analysis at the
genomic facilities of The Human Genome Research
Center (HGRC), at the University of São Paulo. BLAST
searches were performed to determine the closest
known relatives of the partial rRNA gene sequence
obtained in GenBank.
Nucleotide sequence accession numbers
The sequences of the 16S rDNA fragments were deposited
in the GenBank database. The accession numbers of the 4
sequences are as follows (band code in parentheses):
KF054352 (lac1), KF054351 (lac2), KF054353 (lac3) and
KF054350 (lac4).
Statistical analysis
The significance of all results was investigated with one-
way ANOVA, and individual means were compared using
the Tukey’s test (p < 0.01), using the statistical software
Sigma Stat 5.0.
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Results
Plate count data
Table 2 shows the microbial counts obtained for the flasks
that simulated the ascendant, transverse and descendant
colon of the SHIME® reactor. Using traditional selective
growth media, the microbiological analyses revealed that
the administration of L. acidophilus CRL1014 influenced
the composition of the intestinal microbial community.
Plate counts were used to assess the capacity of L.
acidophilus CRL1014 to temporarily colonize the colon
during a simulated long term administration and to
investigate the effects on the composition of the
indigenous microbial community in the SHIME®. As
reflected in the plate count data (Table 2), the adminis-
tration of L. acidophilus to the system induced a signifi-
cant increase (p < 0.01) in lactobacilli and bifidobacteria
counts, with a concentration increase of at least 2 log
CFU in all colon compartments. However, in all colon
compartments, a high increase in clostridia starting
from the second week of the basal period in ascending
colon and first week of the treatment in transverse and
descending colon was observed (Table 2).
For other microbial groups, such as total aerobes, facul-
tative anaerobes, and enterobacteria, there were no signifi-
cant changes in the populations of these microorganisms
during the treatment period.
Effects of the long-term treatment on the Lactobacillus
community structure
DGGE analysis was used to monitor qualitative changes
in the composition and structure of the Lactobacillus
communities in the three compartments simulating the
colon conditions (Figure 1).
Clustering of the specific DGGE fingerprints for lactoba-
cilli (Figure 1) indicated that the treatment had effect on
the composition of the Lactobacillus community, after
4 weeks of treatment with L. acidophilus CRL1014, higher
similarity values (>90%) were found between reactors 3, 4,
Table 2 Average plate count measurements (±SEM), expressed in log CFU mL1, for the different microbial groups,
SHIME compartments and periods
Basal Treatment Washout
1st week 2nd week 1st week 2ndweek 3th week 4th week 1stweek 2ndweek
Ascending colon
Enterococcus spp 5.20a ± 0.01 5.40a ± 0.02 6.30b ± 0.10 7.25c ± 0.04 7.20c ± 0.06 8.05d ± 0.21 7.00c ± 0.02 7.00c ±0.01
enterobacteria 7.35d ± 0.41 6.00c ± 0.30 6.20c ± 0.32 6.40c ± 0.01 6.72c ± 0.22 6.80c ± 0.32 5.68b ± 0.01 4.20a ± 0.05
Lactobacillus spp 5.17a ± 0.30 5.23a ± 0.22 7.78b ± 0.03 7.77b ± 0.01 8.28c ± 0.05 7.88bc ± 0.01 7.20b ± 0.04 5.40a ± 0.04
Bifidobacterium spp 5.80a ± 0.22 6.90b ± 0.55 7.77c ± 0.01 7.86c ± 0.05 7.88c ± 0.06 7.97c ± 0.06 7.68c ± 0.03 7.61c ± 0.04
Clostridium spp 7.68a ± 0.02 8.32b ± 0.02 8.69b ± 0.01 9.39bc ± 0.01 12.39d ± 0.01 12.30d ± 0.02 12.40d ± 0.01 12.39d ± 0.01
Total aerobes 7.14a ± 0.41 7.84a ± 0.05 7.72a ± 0.01 7.42a ± 0.02 7.55a ± 0.04 7.32a ± 0.01 7.30a ± 0.01 7.42a ± 0.05
Facultative anaerobes 7.66a ± 0.03 8.20a ± 0.02 7.80a ± 0.02 7.60a ± 0.04 7.40a ± 0.01 7.30a ± 0.03 7.46a ± 0.02 7.50a ± 0.01
Transverse colon
Enterococcus spp 4.14a ± 0.22 4.44a ± 0.02 7.19b ± 0.01 6.84b ± 0.01 7.45b ± 0.03 7.50b ± 0.05 7.00b ± 0.04 7.00b ± 0.01
enterobacteria 6.23b ± 0.46 5.15a ± 0.15 5.00a ± 0.01 6.30b ± 0.01 6.00b ± 0.01 6.00b ± 0.01 6.84b ± 0.01 6.86b ± 0.02
Lactobacillus spp 5.20a ± 0.02 5.19a ± 0.02 7.72b ± 0.02 7.35b ± 0.05 7.24b ± 0.01 7.17b ± 0.05 8.33b ± 0.05 8.40b ± 0.01
Bifidobacterium spp 5.80a ± 0.07 5.00a ± 0.01 7.18b ± 0.14 7.86b ± 0.05 7.43b ± 0.01 7.31b ± 0.14 7.79b ± 0.05 7.80b ± 0.02
Clostridium spp 6.61a ± 0.01 6.62a ± 0.01 7.27a ± 0.01 8.39b ± 0.01 8.26b ± 0.03 8.53b ± 0.23 10.39c ± 0.01 10.40c ± 0.01
Total aerobes 7.00a ± 0.02 7.20a ± 0.20 7.74a ± 0.02 7.32a ± 0.11 7.82a ± 0.02 7.86a ± 0.03 8.69b ± 0.22 8.64b ± 0.10
Facultative anaerobes 6.32a ± 0.07 6.30a ± 0.01 6.00a ± 0.41 6.20a ± 0.13 6.10a ± 0.22 6.30a ± 0.01 7.80ab ± 0.01 8.10b ± 0.11
Descending colon
Enterococcus spp 4.30a ± 0.02 4.32a ± 0.01 7.08b ± 0.01 6.66b ± 0.02 6.75b ± 0.05 6.76b ± 0.04 7.08b ± 0.02 7.06b ± 0.01
enterobacteria. 7.46b ± 0.06 6.00a ± 0.01 6.15a ± 0.15 6.30a ± 0.01 6.00a ± 0.01 6.00a ± 0.01 5.67ab ± 0.01 5.70ab ± 0.01
Lactobacillus spp 5.36a ± 0.01 5.38a ± 0.02 7.46b ± 0.02 7.23b ± 0.06 7.13b ± 0.09 6.53b ± 0.53 7.20b ± 0.01 7.27b ± 0.08
Bifidobacterium spp 6.79b ± 0.04 5.72a ± 0.12 7.15c ± 0.01 7.53c ± 0.01 6.84bc ± 0.15 7.37c ± 0.03 7.55c ± 0.01 7.47c ± 0.01
Clostridium spp 7.72a ± 0.01 7.74a ± 0.06 8.48b ± 0.01 9.39c ± 0.01 10.50d ± 0.15 10.50d ± 0.02 10.34d ±0.02 10.38d ± 0.44
Total aerobes 7.24a ± 0.07 7.53a ± 0.01 7.44a ± 0.01 7.47a ± 0.42 7.58a ± 0.09 7.86a ± 0.05 8.00a ± 0.01 8.20a ± 0.45
Facultative anaerobes 7.39b ± 0.11 6.30a ± 0.01 6.59a ± 0.01 6.39a ± 0.02 6.40a ± 0.01 6.00a ± 0.03 7.69b ± 0.01 7.63b ± 0.05
Different letters indicate significantly different results (p < 0.01) in same microbial group and same compartment (ascending, transverse, and descending colon),
during basal, treatment and washout period.
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and 5 (Figure 1). Finally, after two wk the treatment period
was finished and the highest similarity values (99 to 91%)
were found in all colon regions between the last week of
treatment and the washout period (Figure 1).
Based on the DGGE fingerprint analysis of the colon
microbial community, several shifts in bands or changes
in band intensity were observed. To identify the bacterial
species that were responsible for those changes, DNA
fragments from bands of interest were excised from the
DGGE gel, isolated, and finally sequenced. We were not
able to obtain sequences from all bands but four. The
successfully sequenced rDNA fragments were marked as
lac 1, lac 2, lac 3, and lac 4. The band marked as lac1 mi-
grates to the same position as the fragment obtained from
pure cultures of L. acidophilus CRL1014 and showed a
99% identity with L.acidophilus (JQ031741.1). The frag-
ments lac2 and lac3 demonstrated high identity (>98%) to
Lactobacillus casei (JQ412731.1) and Lactobacillus
johnsonii (AB186343.1), respectively. Finally, the band
marked “lac 4” was dominant during the whole experi-
mental period and had 99% of similarity with Lactobacillus
sakei (GI,AB609050.1).
Ammonium concentration and fermentation capacity
Short chain fatty acids (SCFA) analysis and ammonium
production are often used to characterize microbial
metabolism.
During the treatment period with L. acidophilus, the
values of concentration of ammonium ion decreased
significantly (p < 0.01) in all the regions investigated
(Figure 2).
Figure 3 depicts the production of acetate, propionic,
and butyric acids during the basal, treatment, and washout
periods in the SHIME® vessels. During treatment with
L. acidophilus CRL 1014, a significant increase (p < 0.01)
occurred in the production of acetate acid in all the reac-
tors analyzed. However, the greatest concentration of
these acids occurred in vessel three, which simulates the
ascending region of the colon. The propionic acid showed
a significant increase (p < 0.01) in reactors 3 and 4
(ascending and transverse colon) and the butyric acid
increased significantly (p < 0.01) in reactors 4 and 5 (trans-
verse and descending colon). In the washout period, the
levels of SCFA diminished in all vessels. The highest SCFA
production consisted of acetic acid in all vessels (Figure 3).
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Figure 1 UPGMA dendrogram illustrating the correlation between the different denaturing gradient gel electrophoresis (DGGE)
profiles from lactobacillus community obtained from the samples of the SHIME® compartments supplemented with the L. acidophilus
CRL 1014 strain throughout model operation. Sequence characterization of the excised fragments indicated the presence of lac 1, L.
acidophilus; lac 2, Lactobacillus casei; lac 3, Lactobacillus johnsonii and Lac 4, Lactobacillus sakei. R3: ascending colon, R4: transverse colon, R5:
descending colon. B1, and B1: basal period, T1, T2, T3, and T4: treatment period with L. acidophilus 1014.
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Figure 2 Average ammonium ion production (ppm) in SHIME® run, during basal, treatment and washout period. Statistically significant
differences among the samples were investigated with one-way ANOVA (samples with the same letter on the top of the bar are not statistically
different, P < 0.05).
Reactor 3 Reactor 4
Reactor 5
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Figure 3 Metabolic activity (short chain fatty acid (SCFA) acetic acid, propionic acid and butyric acid) and lactic acid of the microbial
community in reactor three, four and five from the basal, treatment and washout periods in the SHIME®. Reactor 3: simulates the
ascending colon; reactor 4: simulates the transverse colon; reactor 4: simulates the descending colon. Statistically significant differences among
the samples were investigated with one-way ANOVA. Samples with the same letter on the top of the bar are not statistically different, (p < 0.01).
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However, in reactor 5 the highest increase was in
propionic acid. Lactic acid was only observed for the treat-
ment period in all vessels (ascending, transverse and
descending).
Discussion
The intestinal microbiota is located in difficult-to-access
areas of the digestive tract. Therefore, as it requires inva-
sive methods for collection, it is a limiting factor for a
more precise analysis [29]. An investigative alternative is
the use of continuous or semi-continuous models simu-
lating the large intestine. The continuous models were
validated based on the intestinal contents of sudden
death victims [30]. The advantages of this model include
ease-of-use, the possibility of using radioactive substances
and low cost [29].
The appropriate selection of probiotic strains forms
the basis for further development of supplements and
food products, as well as for planning future clinical
trials. In vitro studies are useful for evaluating the safety
and efficiency of probiotic strains. Recent advances in
science have revealed many mechanisms by which
probiotics exert health-promoting effects in humans and
laboratory animals [6]. In this paper, we evaluated the
interactions of Lactobacillus acidophilus CRL1014 with
the native microbiota, using the Simulator of Human
Intestinal Microbial Ecosystem (SHIME®).
The results with plate count showed that the L. acidoph-
ilus CRL1014 strain is able to modulate the native intes-
tinal microbiota. Lactobacillus spp. and Bifidobacteruim
spp. were increased during the treatment period. The
population of Clostridium spp. was increased 2–3 cycles
log during the treatment period in the three regions of the
colon evaluated. Bacteria belonging to this genus may be
harmful, due to their metabolic activity and the pathogenic
character of some species [31]. Clostridium species may
be involved in inflammatory processes of intestinal dis-
eases [32]. In a previous study with E. faecium CRL 183,
the same behavior was observed [33]. However, according
to Possemiers et al. [34], high clostridia counts are not ne-
cessarily associated with negative health effects, as many
members of the Clostridia group are associated with the
production of health-promoting short chain fatty acids.
Structural analysis of the colon lactobacilli populations
using PCR-DGGE showed that administration of L. acid-
ophilus CRL 1014 affected the lactobacilli populations.
Clustering of the lactobacilli DGGE patterns showed that
samples from the treatment period were grouped together.
The DGGE and sequencing analysis also showed that the
Lactobacillus acidophilus effect was not restricted to the
ascending colon alone, but was also visible in the distal
colon vessels. After the end of the treatment period, it was
possible to observe the higher similarity values (97.73%)
between treatment and washout periods in the colon
ascendant. Lactobacillus acidophilus CRL 1014 probably
temporarily colonized the simulated gut, while the overall
ecological characteristics of the indigenous microbiota
were modulated and preserved.
In this study, beneficial effects of L. acidophilus CRL
1014 were observed in terms of microbial metabolism.
Production of SCFA is considered beneficial to the host,
because these compounds protect against pathogens
[35], stimulate the immune responses [36], decrease
cholesterol synthesis [37], enhance muscular contractions
[38], and may protect the colon against cancer develop-
ment [39].
In all vessels, increased amounts of SFCA (acetate,
propionate and butyrate) during the treatment period
were observed. The rate and amount of SCFA production
depend on the species and number of microorganisms
present in the colon, the substrate source, and the gut
transit time. The acid with the highest production was
acetate. SCFAs are readily absorbed. Acetate, the main
SCFA in the colon, is readily absorbed and transported to
the liver and, therefore, is less metabolized in the colon.
Acetate also enters the peripheral circulation to be metab-
olized by peripheral tissues [40,41].
Specific SCFA may reduce the risk of developing
gastrointestinal disorders, cancer, and cardiovascular dis-
ease. Acetate, the main SCFA in the colon, can increase
cholesterol synthesis after absorption. However, propion-
ate, a gluconeogenerator, can inhibit cholesterol synthesis.
Therefore, substrates that are able to decrease the acetate:
propionate ratio may reduce serum lipids and possibly
cardiovascular disease risk [42].
The ability to reduce serum cholesterol is a highly
desirable attribute of probiotic cultures as a dietary com-
ponent [43]. Certain strains of L. acidophilus have the
ability to assimilate cholesterol. This was shown by the
appearance of cholesterol in the cells during growth,
which was associated with decreases in the concentra-
tions of cholesterol in the growth medium [42]. In a pre-
vious study, our researcher group observed the ability of
Lactobacillus acidophilus CRL 1014 to remove 13% of
the cholesterol in vitro [43]. Binding of cholesterol with
bile acids and inhibition of micelle formation combined
with the effect of fermentation on short chain fatty acid
(SCFA) production were mechanisms that had been pro-
posed to explain the potential cholesterol-lowering effects
of L. acidophilus strains [44,45].
A significant increase in butyrate concentration was
observed in the vessels simulating the transverse and
descendant colon. The same results were observed in
recent investigation with Enterococcus faecium CRL 183
[33]. Butyrate is considered the preferred fuel of the
epithelial cells of the colon, which derive 70% of their
energy from the oxidation of this substrate. Butyrate also
reduces the expression of proinflammatory cytokines of
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tumor necrosis factor-α (TNF-α), TNF-β, interleukine-6
(IL-6), and IL-1β through activation of the nuclear
growth inhibiting factor kB (NF-kB) [42]. In addition, it
has been proposed that butyrate reduces the risk of
colon cancer, due to its ability to inhibit the genotoxic
capacity of nitrosamines and hydrogen peroxide, as well
as to induce different levels of apoptosis, differentiation
and cessation of the cellular cycle of colon cancer in
animal models [46].
Other important observation in terms of the metabolic
activity was the ammonium ion production, which is a
marker for proteolytic activity of the microbial popula-
tion. In the ascending and descending colon, a signifi-
cant (p < 0.01) reduction (29.8 and 20.5%, respectively)
in the ammonium ion production during L. acidophilus
treatment was observed. Usually, colon cancer occurs in
the distal parts, because of higher concentrations of
more hazardous compounds due to proteolysis and a
higher pH, it is often the goal to extend sugar fermenta-
tion towards the distal parts of the colon [47]. During
the treatment with L. acidophilus decrease proteolytic
activity of the microbial population was observed.
Conclusion
This study indicated the usefulness of in vitro methods
that simulate the colon region and showed the positive
influence of L. acidophilus CRL 1014 on microbial me-
tabolism and lactobacilli community composition.
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